Fig. 1From: Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case reportClinical course of rhabdomyolysis and NSCLC. Reduced doses of dabrafenib and trametinib combination treatment prevented the incidence of rhabdomyolysis and tumor progressionBack to article page